NVCR - Company ID 0001645113
NovoCure Ltd (NVCR) reported revenue of $655.35M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $655.35M | +8.3% |
| FY 2024 | $605.22M | +18.8% |
| FY 2023 | $509.34M | -5.3% |
| FY 2022 | $537.84M | +0.5% |
| FY 2021 | $535.03M | +8.2% |
| FY 2020 | $494.37M | +40.7% |
| FY 2019 | $351.32M | +41.6% |
| FY 2018 | $248.07M | +40.1% |
| FY 2017 |
NovoCure Ltd (NVCR) reported revenue of $655.35M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2013 and fiscal 2025, NovoCure Ltd's revenue grew from $10.36M to $655.35M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $177.03M |
| +113.6% |
| FY 2016 | $82.89M | +150.5% |
| FY 2015 | $33.09M | +113.6% |
| FY 2014 | $15.49M | +49.5% |
| FY 2013 | $10.36M | - |